MapLight Therapeutics Files 8-K on Financial Results & Reg FD Disclosure

Ticker: MPLT · Form: 8-K · Filed: Mar 26, 2026 · CIK: 0001770069

Maplight Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyMaplight Therapeutics, INC. (MPLT)
Form Type8-K
Filed DateMar 26, 2026
Risk Levelmedium
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: earnings, financial-condition, regulation-fd, corporate-disclosure

TL;DR

**MapLight Therapeutics just dropped an 8-K with financial results and other key disclosures, so pay attention!**

AI Summary

MapLight Therapeutics, Inc. filed an 8-K on March 26, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). This indicates the company likely released financial results or other material non-public information, which they are now making public. For investors, this filing is crucial as it provides the latest financial health and operational updates, potentially impacting the stock's valuation and future prospects.

Why It Matters

This filing signals that MapLight Therapeutics has disclosed important financial or operational updates, which could directly influence investor perception and stock price. Understanding these details is key for assessing the company's current performance and future outlook.

Risk Assessment

Risk Level: medium — The risk level is medium because while the filing itself is routine, the content of the financial results and disclosures could contain positive or negative news that significantly impacts the stock.

Analyst Insight

A smart investor would immediately review the attached exhibits (EX-99.1 and EX-99.2) to understand the specific financial results and disclosures made by MapLight Therapeutics, Inc. before making any investment decisions.

Key Players & Entities

Forward-Looking Statements

FAQ

What specific items did MapLight Therapeutics, Inc. report under in this 8-K filing?

MapLight Therapeutics, Inc. reported under Item 2.02: Results of Operations and Financial Condition, and Item 7.01: Regulation FD Disclosure, as stated in the filing details.

When was this 8-K filing accepted by the SEC?

The 8-K filing was accepted by the SEC on 2026-03-26 at 07:10:11, according to the filing details.

What is the CIK number for MapLight Therapeutics, Inc.?

The CIK number for MapLight Therapeutics, Inc. is 0001770069, as listed in the company information section of the filing.

What is the business address of MapLight Therapeutics, Inc.?

The business address for MapLight Therapeutics, Inc. is 800 CHESAPEAKE DRIVE, REDWOOD CITY, CA 94063, as provided in the filing.

What is the SIC code for MapLight Therapeutics, Inc. and what does it represent?

The SIC code for MapLight Therapeutics, Inc. is 2834, which represents 'Pharmaceutical Preparations', as indicated in the company information.

Filing Stats: 684 words · 3 min read · ~2 pages · Grade level 10.3 · Accepted 2026-03-26 07:10:11

Key Financial Figures

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On March 26, 2026, MapLight Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company's filings under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On March 26, 2026, the Company updated its corporate presentation for use in meetings with investors, analysts and others. The presentation is available on the Company's website and a copy is furnished as Exhibit 99.2 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01, and Exhibit 99.2 hereto, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company's filings under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, dated March 26, 2026 99.2 Corporate Presentation, dated March 26, 2026 104 Cover Page Interactive Data File (formatted as inline XBRL).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MapLight Therapeutics, Inc. Date: March 26, 2026 By: /s/ Christopher Kroeger Christopher A. Kroeger, M.D. Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing